TOP TEN perturbations for O43829 (Homo sapiens)

Organism: Homo sapiens
Gene: O43829
Selected probe(set): 209724_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of O43829 (209724_s_at) across 5610 perturbations tested by GENEVESTIGATOR:

colorectal cancer study 43 (metastase; brain) / colorectal cancer study 43 (metastase; lung)

Relative Expression (log2-ratio):-2.9616585
Number of Samples:2 / 5
Experimental colorectal cancer study 43 (metastase; brain)
Metastatic tumor tissue obtained from the brain of patients with primary colorectal adenocarcinoma.
Control colorectal cancer study 43 (metastase; lung)
Metastatic tumor tissue obtained from the lung of patients with primary colon adenocarcinoma.

PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample

Relative Expression (log2-ratio):-2.5290203
Number of Samples:8 / 8
Experimental PMA; ionomycine study 2
CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 ?g/ml). ATC code:---
Control unstimulated CD4 memory T-cell sample
Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects.

tumor supernatant activation study 3 / untreated memory CD4 T-cell sample

Relative Expression (log2-ratio):-2.1406765
Number of Samples:4 / 3
Experimental tumor supernatant activation study 3
Memory (CD45RA-) CD4+ T cells isolated from peripheral blood of female healthy donors were incubated for 24 hours in 1:1 mix of tumor supernatant from primary invasive breast ductal carcinoma and X-VIVO 20 medium supplemented with antiCD3/CD28 beads, before harvest for RNA isolation. The tumor supernatant was prepared as followed: fresh surgical specimen was dissociated in X-VIVO 20 medium by GentleMACS dissociator and the resulting suspension was clarified by centrifugation for 15min at 13'000 g. ATC code:---
Control untreated memory CD4 T-cell sample
Memory (CD45RA-) CD4+ T-cells were isolated from peripheral blood of healthy female donors and incubated in X-VIVO 20 medium for 24 hours, before harvest for RNA isolation.

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):2.0788546
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

precursor-B-ALL study 7 (PDX; long-term; >10wk) / precursor-B-ALL study 7 (late relapse; >24m)

Relative Expression (log2-ratio):2.003912
Number of Samples:7 / 8
Experimental precursor-B-ALL study 7 (PDX; long-term; >10wk)
Leukemia cell samples isolated from spleen of patient derived xenografts (PDX) of precursor B-cell acute lymphoblastic leukemia generated in NOD/SCID mice with time to manifestation of leukemia (TTL) more than 10 weeks (long-term). Cell suspensions containing more than 90% leukemia cells as estimated by flow cytometry were prepared from infiltrated spleens of leukemia bearing mice. Briefly, unconditioned NOD/SCID (NOD.CB17-Prkdcscid/NCrCrl) mice with a median age of 10 weeks were transplanted by injection of patient leukemia cells, which were isolated from bone marrow or peripheral blood of pediatric patients with precursor BCP-ALL, into the lateral tail vein. Upon clear evidence for leukemia related morbidity, mice were killed and autopsy was performed. Leukemia was confirmed detecting leukemia cells in bone marrow, spleen and peripheral blood. Time to leukemia (TTL) was determined as weeks from transplant to clinical leukemia manifestation. Donor characteristics: 3 females and 9 males; 1-9 years old; good response to prednison; no fusion gene; remision at day 33; non-high risk group; late relapse group (relapse after 24 months from diagnosis).
Control precursor-B-ALL study 7 (late relapse; >24m)
Leukemia cell samples isolated from bone marrow of pediatric patients with precursor B-cell acute lymphoblastic leukemia (B-ALL) with relapse after 24 months from diagnosis (late relapse). White blood cells were isolated through Ficoll-Hypaque density gradient centrifugation. All diagnostic leukemia samples were obtained before treatment from pediatric de novo B cell precursor ALL patients (BCP-ALL). Samples obtained from studies registred under NCT00430118 and NCT00613457.

E. coli study 2 / unstimulated, normal monocyte-derived macrophage sample

Relative Expression (log2-ratio):-1.9868717
Number of Samples:5 / 7
Experimental E. coli study 2
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours with 2.5 ? 105 heat-killed E. coli.
Control unstimulated, normal monocyte-derived macrophage sample
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours unstimulated.

F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):-1.9829311
Number of Samples:4 / 6
Experimental F. tularensis study 1 (novicida)
Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample

Relative Expression (log2-ratio):1.9666853
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal B-cell sample
MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

heat shock study 1 (LPS) / untreated THP-1 cell sample

Relative Expression (log2-ratio):-1.9651699
Number of Samples:3 / 3
Experimental heat shock study 1 (LPS)
Cultured THP-1 mononuclear cells were treated with heat shock (43?C; 1h) and lipopolysaccharide (1ug/ml; 4h).
Control untreated THP-1 cell sample
Cultured THP-1 mononuclear cells were cultured in basal growth media at 37?C.

elesclomol study 2 / vehicle (DMSO) treated Hs 294T cell sample

Relative Expression (log2-ratio):-1.9079647
Number of Samples:2 / 2
Experimental elesclomol study 2
Hs 294T cells (passage 11) treated with 100nM elesclomol at timepoint 6 hours. ATC code:---
Control vehicle (DMSO) treated Hs 294T cell sample
Hs 294T cells (passage 11) treated with 0.01% DMSO at timepoint 6 hours.